A review on the role of LINC01133 in cancers

Long Intergenic Non-Protein Coding RNA 1133 (LINC01133) is a long non-coding RNA (lncRNA) which interacts with miR-106a-3p, miR-576-5p, miR-495-3p, miR-205, miR-199a-5p, miR-4784, miR-30a-5p, miR-199a, miR-30b-5p, miR-216a -5p and miR-422a, thus increasing expression of mRNA targets of these miRNAs. LINC01133 can affect cancer metastasis through regulation of epithelial-mesenchymal transition program. Dysregulation of this lncRNA has been repeatedly detected in the process of tumorigenesis. In this review, we summarize the results of various studies that reported dysregulation of LINC01133 in different samples and described the role of this lncRNA as a marker for these disorders.


Introduction
Long non-coding RNAs (lncRNAs) have been vastly investigated for their effects in the carcinogenesis [1]. These transcripts have sizes larger than 200 nt and are mainly located in the nucleus [2]. Although lncRNAs are expressed at low levels, they participate in transcriptional and post-transcriptional regulation of gene expression via interacting with other types of biomolecules, namely nucleic acids or proteins [3]. They can enhance or interfere with establishment of transcription loops. Moreover, they are able to induce or suppress recruitment of other regulators [4,5] and affect mRNA splicing. Finally, they serve as origin for microRNAs (miRNAs) [6]. Notably, lncRNAs can affect tumorigenesis through acting as oncogenes or tumor suppressors [7].
Long Intergenic Non-Protein Coding RNAs (LINC RNAs), as a class of lncRNAs have been found to interplay with chromatin modification complexes or RNA binding proteins [8]. These transcripts can change gene expression programs. Previous studies have reported distinctive expression profile of LINC RNAs in primary and metastatic tumors [8,9] and the role of these transcripts in the metastases [10][11][12]. Moreover, expression of these transcripts is finely controlled in the course of development and in response to different signals [13]. LINC01133 is an example of these transcripts. The gene coding this lncRNA is located on 1q23.2. This lncRNA has four transcript variants with sizes of 1996 bp, 1418 bp, 1405 bp and 1266 bp, respectively (http:// www. ensem bl. org/ Homo_ sapie ns/ Gene/ Summa ry? db= core;g= ENSG0 00002 24259;r= 1: 15995 8035-15998 4750).
LINC01133 has been found to be dysregulated in the process of tumorigenesis. However, it has different patterns of expression in various malignancies, or even within a certain type of malignancy. In this review, we summarize the results of various studies that reported dysregulation of LINC01133 in cell line originated from different cancer types, animal studies and investigations in human samples.

Cell line studies
In vitro and functional studies in different cell lines have reported either oncogenic ( Fig. 1) or tumor suppressor role (Fig. 2) for LINC01133. In the following sections, we describe the role of LINC01133 in different cancers.

Open Access
Cancer Cell International *Correspondence: Mohammad.taheri@uni-jena.de; majimokh@gmail.com Fig. 1 Oncogenic roles of LINC01133 in cancers. Detailed information about mechanism of involvement of LINC01133 in these cancers is provided in Table 1. ↑ shows up-regulation. ┴ shows inhibitory effect Fig. 2 Tumor suppressor roles of LINC01133 in cancers. Detailed information about mechanism of involvement of LINC01133 in these cancers is provided in Table 1. ↑ shows up-regulation.┴ shows inhibitory effect

Gynecological cancers
Expression of LINC01133 has been found to be enhanced in epithelial ovarian cancer cell lines. Functionally, LINC01133 enhances migration and invasiveness of ovarian cancer cells. LINC01133 and miR-495-3p have been shown to reciprocally repress expression of each other. LINC01133 can interact with miR-495-3p to enhance metastatic ability of ovarian cancer cells via regulation of TPD52 [14]. A microarray-based study in ovarian cancer has shown differential expression of LINC01133 and miR-205 in ovarian cancer samples versus non-cancerous samples [15]. Contrary to the study conducted by Liu et al. [14], LINC01133 has been shown to repress proliferation, invasiveness and migration of ovarian cancer cells [15]. Functionally, LINC01133 could bind with miR-205 and subsequently regulate expression of LRRK2 [15].
Over-expression of LINC01133 in cervical cancer cells has increased their proliferation and metastatic ability while reducing their apoptosis. LINC01133 silencing has inhibited their malignant phenotype. Functionally, up-regulation of LINC01133 results in reduction of miR-30a-5p levels and enhancement of FOXD1 levels [16].
LINC01133 has also been shown to regulate malignant behavior of triple negative breast cancer cells. In fact, LINC01133 could sufficiently promote phenotypic and growth features of cancer stem cells. This lncRNA directly mediates the mesenchymal stem/stromal cellsinduced miR-199a-FOXP2 axis. LINC01133 can also regulate expression of the pluripotency-determining gene KLF4 [17].
LINC01133 has also been revealed to be up-regulated in pancreatic cancer cells in association with higher DKK1 methylation and up-regulation of genes involved in the Wnt signaling pathway. LINC01133 binds with DKK1 promoter, inducing H3K27 trimethylation and decreasing its expression. However, Wnt-5a, MMP-7, and β-catenin levels have been found to be up-regulated following LINC01133 binding. Over-expression of LINC01133 has promoted proliferative potential and invasiveness of pancreatic cancer cells [18].

Hepatocellular carcinoma
Up-regulation of LINC01133 in hepatocellular cancer cells has enhanced proliferation of these cells and induced aggressive phenotype in these cells. Mechanistically, LINC01133 sponges miR-199a-5p and increases expression of SNAI1, facilitating epithelial-mesenchymal transition (EMT) program in these cells. Moreover, LINC01133 has a functional interaction with Annexin A2 (ANXA2) to induce activity of ANXA2/STAT3 axis [19].

Lung cancer
LINC01133 silencing has been shown to decrease proliferative ability, migratory potential and invasiveness of non-small cell lung cancer cells and induce cell cycle arrest at G1/S stage. Mechanistically, LINC01133 has interaction with EZH2 and LSD1 to recruit these proteins to the promoter regions of KLF2, P21 or E-cadherin promoters to suppress their transcription [20].

Gastrointestinal cancers
LINC01133 has been shown to be down-regulated in gastric cancer cell lines. LINC01133 silencing has enhanced proliferation and migration, and induced the EMT program in gastric cancer cells, while its up-regulation has induced opposite impact. Based on the bioinformatics analyses and luciferase assay, miR-106a-3p has been found to be directly targeted by LINC01133. Mechanistically, miR-106a-3p can target adenomatous polyposis coli (APC) gene and decrease its expression. Taken together, LINC01133/miR-106a-3p has been found as a functional axis in suppression of EMT and metastasis through decreasing activity of the Wnt/β-catenin pathway via affecting APC levels [21]. Another study has shown that LINC01133 can up-regulate SST via binding to miR-576-5p. Up-regulation miR-576-5p or inhibition of SST has upturned the biological effects of LINC01133 in gastric cancer cells. Thus, LINC01133 up-regulation can suppress development of gastric cancer through decreasing expression of miR-576-5p and enhancing SST levels [22].

Animal studies
Up-regulation of LINC01133 hepatocellular cancer cells has enhanced growth of hepatocellular carcinoma and lung metastasis in animal models, while its silencing has led to opposite effects [19]. An experiment in animal model of epithelial ovarian cancer has shown that upregulation of this lncRNA has enhanced the metastatic ability of cells [14]. However, another study has reported enhancement of tumor weigh and volume as well as increase in metastasis following LINC01133 silencing [15].
Up-regulation of LINC01133 has reduced progression and metastasis of gastric cancer cells [21]. Similarly, experiments in an animal model of breast cancer have revealed that down-regulation of LINC01133 enhances the metastatic ability of malignant cells [25]. In order to assess the impact of LINC01133 in inhibition of colorectal cancer cells metastasis in vivo, Kong et al. have

Human studies
Expression of LINC01133 has been shown to be downregulated in clinical samples obtained from gastric cancer patients in correlation with progression of gastric cancer and metastasis [21]. Similar results have been obtained from expression assays in nasopharyngeal cancer [26], oral [32]/esophageal squamous cell carcinoma [37] and colorectal cancer [38] (Table 3). Through analysis of whole genome sequencing data of hepatocellular cancer samples and matched noncancerous specimens, Yin et al. have reported increased in genomic copy numbers of LINC01133 in cancerous samples in correlation with up-regulation of LINC01133 and poor prognosis of affected individuals [19]. Similarly, assessment of expression profile of cervical cancer samples in TCGA database has revealed up-regulation of LINC01133 levels in these samples [24]. Another study has confirmed up-regulation of LINC01133 in cervical cancer samples and reported association between its levels and advanced T stage and negative HPV infection [16]. Besides, LINC01133 has been found to be up-regulated in pancreatic cancer and osteosarcoma. Dysregulation of LINC01133 in clinical samples has been frequently associated with malignant features and poor patients' outcome. However, different experiments in in ovarian, breast and lung cancers have reported conflicting results regarding the pattern of expression of LINC01133 in cancerous versus non-cancerous samples ( Table 3).
LINC01133 levels have been used to predict prognosis of cancer in different tissues (reviewed in Table 3). Dysregulation of LINC01133 has been found to affect clinical outcomes in different studies. However, since it can exert dissimilar roles in different tissues, the impact of LINC01133 down-/up-regulation on clinical outcome depends on the tissue origin.
Data about the mechanisms of dysregulation of LINC01133 in cancer is scarce. However, the presence of CNVs has been shown to affect its expression [19]. Moreover, there is no clear elucidation for tissue-specific effects of this lncRNA in the carcinogenesis. Based on the presence of conflicting results about the role of LINC01133 in the evolution of cancer, therapeutic targeting of this lncRNA should be considered with caution. Moreover, it is necessary to design novel methods for specific delivery of LINC01133-targeting therapeutic modalities to target tissues.